Acumen Pharmaceuticals Targets Late 2026 for ALTITUDE-AD Phase II Readout, Secures $36M for EBD Program

Acumen Pharmaceuticals announced its goal to release Phase II data for its ALTITUDE-AD program in late 2026, while also securing $36 million in funding to advance its EBD program.